Oncology Central

Evolving paradigms in cancer immunotherapy: free live simulcast

0

PROGRAM OVERVIEW

This case-based enduring activity will cover the treatment and management of patients with advanced solid tumors who are treated or eligible for treatment with immunotherapy.

Register now

Click here to register for this free CME-accredited event.
Would you like access to more immuno-oncology content?

Target audience:

This activity is designed to meet the educational needs of oncologists, oncology pharmacists, oncology nurses and other healthcare professionals involved in the management of patients with advanced solid tumors who are treated or eligible for treatment with immunotherapy.

What will you learn?

Upon completion of the program, attendees should be able to:

  • Visually illustrate the dynamic interactions between cancer cells, tumor microenvironment and the immune system and how new immune checkpoint inhibitors work differently from chemotherapy.
  • Review applications and limitations of current biomarkers tests (PD-L1 assay) and investigational assays for guiding the use of PD-1/PD-L1 blockade.
  • Critically evaluate clinical data of emerging PD-1/PD-L1 inhibitors, with a focus on the modality of response and the rationale for combination therapy.
  • Optimize dosing and tolerability, and assess and manage immune-related adverse events associated with PD-1/PD-L1 blockade.

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This CME activity was planned and produced in accordance with the ACCME Essentials.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this enduring activity for a maximum of 3.0 AMA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.

Following the agreement on the mutual recognition of credits between the American Medical Association and the UEMS-EACCME®, European physicians can earn their ECMEC®s by completing e-learning programs from accredited providers from the United States that have been certified for AMA PRA Category 1 Credits™

NURSING CREDIT INFORMATION

Purpose:
This program would be beneficial for nurses involved in the treatment and management of patients with advanced solid tumors who are treated or eligible for treatment with immunotherapy.

CNE Credits:
3.0 ANCC Contact Hour(s)

CNE Accreditation Statement:
Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Awarded 3.00 contact hour(s) of continuing nursing education of RNs and APNs.

PHARMACY CREDIT INFORMATION


Amedco is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  Successful completion of this program qualifies for up to 3 contact hours.  Full attendance is required.  No partial contact hours will be awarded for partial attendance. UAN# 0453-9999-17-490-H04-P(K)

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME)
Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF CONFLICTS OF INTEREST

Dr. Bernard Escudier:

  • Consulting fees from Pfizer, BMS, Novartis, Ipsen, Bayer, Roche, Eisai and Acceleron

Dr. Ignacio Melero:

  • Consulting fees from BMS, Lilly, Bayer, Alligator, Genmab, Roche, Tusk, and Servier
  • On the Speakers Bureau for MSD, BMS, Celgene, and Roche
  • Conducted research for Alligator, Tusk, Pfizer, and Roche.

Dr. Camillo Porta:

  • Consulting fees from Novartis, Pfizer, BMS, Ipsen, Eisai, Janssen, Peloton, EUSA
  • On the Speakers bureau for Novartis, Pfizer, BMS, Ipsen, Eisai, Janssen
  • Has contracted research with Pfizer

Dr. Peter Schmid:

  • Nothing to disclose

CME Content Review
The content of this activity was independently peer reviewed.

The reviewer of this activity has nothing to disclose.

CNE Content Review
The content of this activity was independently peer reviewed.

The nurse reviewer of this activity has nothing to disclose.
The staff, planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Matthew Frese, General Manager of Med Learning Group has nothing to disclose.
Christina Gallo, SVP Educational Development for Med Learning Group has nothing to disclose.
Lauren Welch, MA, VP of Accreditation and Outcomes for Med Learning Group has nothing to disclose.
Chris Drury, MS, MA, Medical Director for Med Learning Group has nothing to disclose.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

During the course of this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.

METHOD OF PARTICIPATION

There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures.
2. Participate in the activity.
3. Submit the evaluation form to the Med Learning Group.

You will receive your certificate via email immediately upon completion of the activity.

DISCLAIMER

Med Learning Group makes every effort to develop CME activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For CME questions, please contact: Med Learning Group at info@medlearninggroup.com.

Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/

For more information and to register, please click here.

Share:

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.